Toward antiviral strategies that resist viral escape

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 4, 2000, Pages 1097-1099

  Endy, Drew ^a,b   Yin, John ^a  

^a University of Wisconsin Madison   (United States)

^b The Molecular Sciences Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COMPLEMENTARY RNA; RNA POLYMERASE; VIRUS RNA;

ARTICLE; BACTERIOPHAGE T7; COMPUTER SIMULATION; DRUG DESIGN; DRUG TARGETING; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS MUTATION;

ANTIVIRAL AGENTS; BACTERIOPHAGE T7; COMPUTER SIMULATION; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA COLI; RNA, ANTISENSE; RNA, VIRAL; VIRUSES;

EID: 0034117883     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.4.1097-1099.2000     Document Type: Article

References (24)

1. Bonhoeffer, S., R. M. May, G. M. Shaw, and M. A. Nowak. 1997. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. USA 94:6971-6976.
2. Bull, J., A. Jacobson, M. Badgett, and I. Molineux. 1998. Viral escape from antisense RNA. Mol. Microbiol. 28:835-846.
3. Cameron, D. W., A. J. Japour, Y. Xu, A. Hsu, J. Mellors, C. Farthing, C. Cohen, D. Poretz, M. Markowitz, S. Follansbee, J. B. Angel, D. McMahon, D. Ho, V. Devanarayan, R. Rode, M. Salgo, D. J. Kempf, R. Granneman, J. M. Leonard, and E. Sun. 1999. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13:213-224.
4. Daly, T. J., R. C. Doten, J. R. Rusche, and M. Auer. 1995. The amino terminal domain of HIV-1 Rev is required for discrimination of the RRE from nonspecific RNA. J. Mol. Biol. 253:243-258.
5. Domingo, E., L. Menéndez-Arias, M. Quiñones-Mateu, A. Holguín, M. Gutiérrez-Rivas, M. Martínez, I. Novella, and J. Holland. 1997. Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. Prog. Drug Res. 48:99-128.
6. Endy, A., D. Kong, and J. Yin. 1997. Intracellular kinetics of a growing virus: a genetically structured simulation for bacteriophage T7. Biotechnol. Bioeng. 55:375-389.
7. Endy, D. 1997. Development and application of a genetically-structured simulation for bacteriophage T7. Ph.D. thesis. Dartmouth College, Hanover, N.H.
8. Freier, S. M., W. F. Lima, S. S. Yogesh, T. Vickers, M. Zounes, P. D. Cook, and D. J. Ecker. 1992. Thermodynamics of antisense oligonucleotide hybridization, p. 95-107. In R. P. Erickson and J. G. Izant (ed.), Gene regulation: biology of antisense RNA and DNA. Raven Press, Ltd., New York, N.Y.
9. Heinz, B. A., R. R. Rueckert, D. A. Shepard, F. J. Dutko, M. A. McKinlay, M. Fancher, M. G. Rossmann, J. Badger, and T. J. Smith. 1989. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J. Virol. 63:2476-2485.
10. Hjalt, T. A., and E. G. Wagner. 1995. Bulged-out nucleotides in an antisense RNA are required for rapid target RNA binding in vitro and inhibition in vivo. Nucleic Acids Res. 23:580-587.
11. Ho, D. D., T. Toyoshima, H. Mo, D. J. Kempf, D. Norbeck, C. M. Chen, N. E. Wideburg, S. K. Burt, J. W. Erickson, and M. K. Singh. 1994. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68:2016-2020.
12. Iversen, A. K., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
13. Jeffries, D. J., and E. De Clercq (ed.). 1995. Antiviral chemotherapy. John Wiley & Sons, Chichester, England.
14. Larder, B., K. Coates, and S. Kemp. 1991. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J. Virol. 65:5232-5236.
15. Larder, B. A., P. Kellam, and S. D. Kemp. 1993. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 365:451-453.
16. Lima, W. F., B. P. Monia, D. J. Ecker, and S. M. Freier. 1992. Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry 31:12055-12061.
17. Moutouh, L., J. Corbeil, and D. D. Richman. 1996. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc. Natl. Acad. Sci. USA 93:6106-6111.
18. Murray, J. A. H. 1992. Antisense RNA and DNA. Wiley-Liss, Inc., New York, N.Y.
19. Patzel, V., and G. Sczakiel. 1998. Theoretical design of antisense RNA structures substantially improves annealing kinetics and efficacy in human cells. Nat. Biotechnol. 16:64-68.
20. Perelson, A., A. Neumann, M. Markowitz, J. Leonard, and D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
21. Richman, D. D. (ed.). 1996. Antiviral drug resistance. John Wiley &. Sons, Chichester, England.
22. Saunders, J., and J. M. Cameron. 1995. Recent development in the design of antiviral agents. Med. Res. Rev. 15:497-531.
23. Tomizawa, J. 1984. Control of ColE1 plasmid replication: the process of binding of RNA 1 to the primer transcript. Cell 38:861-870.
24. Uhlmann, E., and A. Peyman. 1990. Antisense oligonucleotides: a new therapeutic principle. Chem. Rev. 90:543-584.